<?xml version="1.0" encoding="UTF-8"?>
<p id="Par84">The ACCoRd study aims to investigate the aforementioned treatment strategy within a population of participants with measurable, by IMWG criteria, relapsed MM requiring therapy who had undergone ASCT in first-line treatment and progressed for the first time at least 12 months after undergoing ASCT. The study will be conducted within an adult population (18 years or older), capable of giving written informed consent, with Eastern Cooperative Oncology (ECOG) Performance Status (ECOG PS) 0â€“2 and adequate full blood count (FBC), as well as satisfactory renal, hepatobiliary, pulmonary and cardiac function.</p>
